Month: February 2024

Obamacare and GLP-1 meds; China’s Obesity Crisis; India’s GLP-1 Drugmakers; Bariatric Surgery cures Diabetes; Corporate Ozempic

Obamacare and GLP-1 meds; China’s Obesity Crisis; India’s GLP-1 Drugmakers; Bariatric Surgery cures Diabetes; Corporate Ozempic

February 25, 2024 No Comments

AT A GLANCE STAT reports ‘…Obamacare insurance is considering a technical change that would require insurers to cover obesity drugs in a market of more than 20 million Americans.’ Goldman Sachs analysts are featured by Reuters that weight-loss drugs ‘…could boost gross domestic product by 1%.’ Marketing guru Scott Galloway writes ‘…Nobody I know is on Ozempic. Yet, nearly everyone I know is on Ozempic.’ The Wall Street Journal notes China

Read More »
Novo’s-$35B-Spending-Spree;-Mounjaro-Launches-in-Britain;-the-Obesity-Drug-Arms-Race;-Hip-Surgery-and-Semaglutide;-Kids-on-Wegovy

Novo’s $35B Spending Spree; Mounjaro Launches in Britain; the Obesity Drug-Arms Race; Hip Surgery and Semaglutide; Kids on Wegovy

February 18, 2024 No Comments

AT A GLANCE Reuters reports Novo Holdings, the controlling shareholder of Danish obesity drugmaker Novo Nordisk, plans to invest about $35 billion by 2030. Eli Lilly launches Mounjaro in Britain this week, for eligible private and NHS patients, from Reuters. Sy Mukherjee at Fast Company notes it is ‘…just the beginning for biopharma’s obesity-drug arms race.’ Patients on semaglutide undergoing hip replacement had lower readmission and

Read More »
Ro Prescribes Compounded Semaglutide; Tirzetapide for Fatty Liver; Obesity Center of Excellence; No-Zempic; AMG133 and Survodutide.

Ro Prescribes Compounded Semaglutide; Tirzetapide for Fatty Liver; Obesity Center of Excellence; No-Zempic; AMG133 and Survodutide.

February 11, 2024 No Comments

AT A GLANCE STAT reports on Eli Lilly drug trial of tirzetapide as a treatment for the liver disease MASH. Business Insider reporter Shelby Livingston notes ‘…startup Ro just started prescribing “compounded” semaglutide, an alternative to Ozempic.’ Milliman, an international actuarial and consulting firm based in Seattle, Washington, explores the concept of an obesity center of excellence. No-zempic is leaving lots of people behind, from

Read More »
Bariatric Surgery Numbers increase in 2022; Wegovy for Depression; Doctors have Fatphobia; Disparities in Obesity Meds; Increased GLP-1 Availability from Novo Nordisk

Bariatric Surgery Numbers increase in 2022; Wegovy for Depression; Doctors have Fatphobia; Disparities in Obesity Meds; Increased GLP-1 Availability from Novo Nordisk

February 2, 2024 No Comments

AT A GLANCE Elaine Chen at STAT asks ‘Can Wegovy treat depression as well as obesity?’ The New York Times reports 750,000 state employees in North Carolina will no longer have insurance coverage for GLP-1 medications, as of April 1 2024. Novo Nordisk ‘…had started to increase the availability of its blockbuster obesity drug Wegovy for new patients in the United States…’ from Andrew Joseph at

Read More »
Categories
Archives
Scroll to Top
Skip to content